Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01297491 · ClinicalTrials.gov registry record · Phase 2
Safety and Efficacy of BKM120 in Patients With Metastatic Non-small Cell Lung Cancer
A Phase 2 study, sponsored by Novartis Pharmaceuticals.
- Completed
- Registry status
- Phase 2
- Development phase
- 63
- Enrollment target
NCT01297491 is a Phase 2 study that has completed, run by Novartis Pharmaceuticals. The registered enrollment target is 63 participants.
The verdict
NCT01297491, a Phase 2 study, has completed, sponsored by Novartis Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 63 participants
- Enrollment target
Study Summary
The purpose of this two-stage phase II study is to assess the efficacy of BKM120, as measured by determining the progression free survival (PFS), in patients with pretreated metastatic Non-small Cell Lung Cancer (NSCLC) that exhibits PI3K pathway activation. BKM120 will be investigated in two groups of NSCLC patients according to the histology of the cancer: squamous and non-squamous.
Interventions
- DRUG BKM120
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 63 participants |
| Start Date | 2011-05 |
| Est. Completion | 2014-10 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01297491
The ClinicalTrials.gov registry entry for NCT01297491 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 63 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Novartis Pharmaceuticals, which has 1,375 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which BKM120 is the first listed.
NCT01297491 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01297491 about?
NCT01297491 is a clinical study titled "Safety and Efficacy of BKM120 in Patients With Metastatic Non-small Cell Lung Cancer". The purpose of this two-stage phase II study is to assess the efficacy of BKM120, as measured by determining the progression free survival (PFS), in patients with pretreated metastatic Non-small Cell Lung Cancer (NSCLC) that exhibits PI3K pathway activation. BKM120 will be investigated in two groups...
What is the current status of trial NCT01297491?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 63 participants. The study started on 2011-05. Estimated completion is 2014-10.
What interventions are being tested in trial NCT01297491?
The interventions under investigation include: BKM120 (DRUG).
Who is sponsoring clinical trial NCT01297491?
This trial is sponsored by Novartis Pharmaceuticals, which has 1,375 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.